LLY Eli Lilly
- Official Name: ELI LILLY AND COMPANY
- Headquarters: Lilly Corporate Ctr, Drop Code 1094, INDIANAPOLIS, IN, 46285 US
- CEO: David A. Ricks
- Website: lilly.com
- Key Investor: PNC FINANCIAL SERVICES GROUP, INC. | 10.68%
- Dedicated Investor: LILLY ENDOWMENT INC | 100%
Match Results
| Date | League | Week | Opponent | Result | Score |
|---|---|---|---|---|---|
| 2025-07-15 | 1 | Won by 1.485 | 0.622 - (0.863) | ||
| 2025-07-22 | 2 | Lost by 1.727 | 1.457 - 3.184 | ||
| 2025-07-29 | 3 | Lost by 4.303 | (2.272) - 2.031 | ||
| 2025-07-29 | 2R | Lost by 6.678 | (5.321) - 1.357 | ||
| 2025-08-05 | 4 | Won by 2.977 | 2.823 - (0.154) | ||
| 2025-08-07 | 1R | Lost by 13.781 | (10.430) - 3.351 | ||
| 2025-08-12 | 5 | Won by 0.443 | 0.329 - (0.114) | ||
| 2025-08-19 | 6 | Won by 8.814 TOTW | 11.298 - 2.484 | ||
| 2025-08-26 | 7 | Won by 1.644 TOTW | 4.545 - 2.901 | ||
| 2025-09-02 | 8 | Lost by 3.542 | (0.113) - 3.429 | ||
| 2025-09-03 | 1R | Won by 1.312 | 0.243 - (1.069) | ||
| 2025-09-09 | 9 | Won by 2.208 | 2.208 - 0.000 | ||
| 2025-09-16 | 10 | Won by 1.163 | 2.318 - 1.155 | ||
| 2025-09-17 | 2R | Won by 0.260 | (0.577) - (0.837) | ||
| 2025-09-23 | 11 | Lost by 2.279 | (2.638) - (0.359) | ||
| 2025-09-30 | 12 | Won by 2.733 | 2.132 - (0.601) | ||
| 2025-10-01 | QF | Won by 7.240 | 7.918 - 0.678 | ||
| 2025-10-07 | 13 | Won by 10.569 TOTW | 9.513 - (1.056) | ||
| 2025-10-14 | 14 | Lost by 1.954 | (3.845) - (1.891) | ||
| 2025-10-15 | SF | Won by 0.503 | 1.869 - 1.366 | ||
| 2025-10-21 | 15 | Lost by 0.029 | (1.548) - (1.519) | ||
| 2025-10-22 | F | Won by 1.225 | 1.678 - 0.453 |
Latest News

Hims & Hers: A Healthcare Behemoth In The Making
Hims & Hers Health is building a vertically integrated consumer health distribution platform. Read why I am bullish about HIMS stock right now.
Eli Lilly Says FDA Approves Mounjaro, Dual GIP And GLP-1 Hormone Receptor Agonist, To Lower Risk Of Major Adverse Cardiovascular Events In Adults With Type 2 Diabetes
Mounjaro is the first and only GIP and GLP-1 receptor agonist proven to lower heart attack, stroke or cardiovascular death risk in adults with type 2 ...

Biohaven: Buy Reiterated On Opakalim License Agreement For Epilepsy And More
Biohaven Ltd. maintains a Buy rating, driven by pivotal trial progress in protein degraders and a key licensing deal for its Kv7 platform. Click here ...

What's going on in today's session: S&P500 movers
Get insights into the S&P500 index performance on Wednesday. Explore the top gainers and losers within the S&P500 index in today's sessio...

Obesity Drug Alert: Eli Lilly Study Shows Sustained Zepbound Treatment Reduces Hospital Visits, Medical Costs
New Eli Lilly study reveals that Zepbound significantly lowers monthly healthcare costs for older adults with overweight or obesity.

Eli Lilly Stock Pulls Back After Hitting Record Highs Last Week
Eli Lilly and Co. shares are trading lower Wednesday, pulling back from last week's record high despite positive real-world data on Zepbound.

Wall Street Lunch: Meta Settles Minors' Addiction, Data Privacy Claims For $12.7B
Meta Platforms (META) has reached a settlement with state attorneys general over allegations that Facebook and Instagram were intentionally designed t...